1. From gut to plaque: gut microbiome's impact on atherosclerosis development and progression. Literature review

Авторлар

  • A. Issilbayeva National Laboratory Astana, Center for life sciences, Nazarbayev University, Astana, Kazakhstan, NpJSC Astana Medical University, Astana, Kazakhstan
  • A. Ainabekova National Laboratory Astana, Center for life sciences, Nazarbayev University, Astana, Kazakhstan, NpJSC Astana Medical University, Astana, Kazakhstan

Жүктеулер

Аңдатпа

Background. Atherosclerosis remains the leading cause of cardiovascular mortality worldwide. This review examines the emerging role of the gut microbiome in atherosclerosis pathogenesis. Recent advances in sequencing technologies have enabled deeper examination of complex interactions between intestinal microbial communities and cardiovascular health.

Methods. This review followed jllpb guidelines, searching PubMed, Scopus, Web of Science, and Embase databases through March 2024. Search terms included "gut microbiome," "atherosclerosis," and related concepts. Studies examining relationships between gut microbiome composition and AS were included, with data extracted using standardized forms and organized into four categories for qualitative synthesis.

Results. Research reveals atherosclerosis patients exhibit reduced bacterial diversiW\ and altered )irmicutes WR %acteroidetes ratios SpeciʖF WD[onomic signatures include increased Enterobacteriaceae and decreased butyrate-producing bacteria. Key microbial metabolites LQʗuence atherosclerosis development short chain fatty acids demonstrate anti LQʗammatory properties trimethylamine 1 R[ide enhances macrophage cholesterol accumulation bile acids modulate lipid metabolism and lipopolysaccharides trigger LQʗammatory cascades involved LQ plaque formation

Conclusion. Understanding gut microbiome contributions to atherosclerosis pathogenesis offers new possibilities for prevention and treatment through microbiota modulation RU targeting speciʖF microbial metabolites representing D paradigm shift toward personalized approaches considering interactions between genetics, environment, and microbiome. '2, %6. ,, Issilbayeva A.

Кілт сөздер

Atherosclerosis, Gut, Microbiome, Short-Chain, Fatty, Acids, Trimethylamine-N-oxide, Bile, Acids, Lipopolysaccharides

Әдебиеттер тізімі

  1. Libby P. The changing land-scape of atherosclerosis. Na-WXUH $SU GRLV
  2. Chaiter Y, Fink DL, Machluf Y. Vas-FXODUPHGLFLQHLQWKHVWFHQWXU Embracing comprehensive vascula-ture evaluation and multidisciplinary treatment. World J Clin Cases. 6HS GRL ZMFFYL
  3. Lechner K, von Schacky C, McKen-zie AL, et al. Lifestyle factors and KLJKULVN DWKHURVFOHURVLV 3DWK-ways and mechanisms beyond tra-ditional risk factors. Eur J Prev &DUGLRO 0DU GRL
  4. Rahman MM, Islam F, Or-Rashid MH, et al. The Gut Microbiota (Microbi-ome) in Cardiovascular Disease and Its Therapeutic Regulation. Front Cell ,QIHFW 0LFURELRO GRLIFLPE
  5. Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut Microbiota in Hyper-WHQVLRQ DQG $WKHURVFOHURVLV $ 5H-YLHZ 1XWULHQWV 6HS GRLQX
  6. Salazar J, Morillo V, Suarez MK, et al. Role of Gut Microbiome in Ath-HURVFOHURVLV 0ROHFXODU DQG 7KHU-apeutic Aspects. Curr Cardiol Rev. HGRL ;
  7. Michels N, Zouiouich S, Vanderbau-whede B, Vanacker J, Indave Ruiz BI, Huybrechts I. Human microbiome DQG PHWDEROLF KHDOWK $Q RYHUYLHZ of systematic reviews. Obes Rev. $SU H GRL obr.13409
  8. Singh RK, Chang HW, Yan D, et al. In-ʗXHQFHRIGLHWRQWKHJXWPLFURELRPH and implications for human health. - 7UDQVO 0HG $SU GRLV
  9. Witkowski M, Weeks TL, Hazen SL. Gut Microbiota and Cardio-vascular Disease. Circ Res. Jul 31 GRL CIRCRESAHA.120.316242
  10. Schoeler M, Caesar R. Dietary lip-ids, gut microbiota and lipid metab-olism. Rev Endocr Metab Disord. 'HF GRL s11154-019-09512-0
  11. Arnold JW, Roach J, Azcarate-Peril MA. Emerging Technologies for Gut Microbiome Research. Trends Mi-FURELRO 1RY GRLMWLP
  12. Integrative HMPRNC. The Integra-tive Human Microbiome Project. Na-WXUH 0D GRLV
  13. Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The Gut Microbio-WD DQG ,QʗDPPDWLRQ $Q 2YHUYLHZ Int J Environ Res Public Health. 2FW GRL ijerph17207618
  14. Cretoiu D, Ionescu RF, Enache RM, Cretoiu SM, Voinea SC. Gut Microbi-ome, Functional Food, Atheroscle-URVLVDQG9DVFXODU&DOFLʖFDWLRQV,V There a Missing Link? Microorgan-LVPV6HS GRLPL-croorganisms9091913
  15. Mao Y, Kong C, Zang T, et al. Impact of the gut microbiome on atheroscle-URVLVP/LIH-XQ GRLPOI
  16. Lewis CV, Taylor WR. Intestinal bar-%8//(7,12)685*(5<,1.$=$.+67$1ɫ 11 FROM GUT TO PLAQUE: GUT MICROBIOME'S IMPACT ON ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSION. LITERATURE REVIEW rier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 'HF ++ GRLDMSKHDUW
  17. Tang WH, Kitai T, Hazen SL. Gut Mi-crobiota in Cardiovascular Health and Disease. Circ Res. Mar 31 GRL CIRCRESAHA.117.309715
  18. Al Samarraie A, Pichette M, Rous-seau G. Role of the Gut Microbiome in the Development of Atherosclerot-ic Cardiovascular Disease. Int J Mol 6FL 0DU GRL ijms24065420
  19. Wu WK, Ivanova EA, Orekhov AN. Gut PLFURELRPH $ SRVVLEOH FRPPRQ therapeutic target for treatment of atherosclerosis and cancer. Semin &DQFHU %LRO 0D GRLMVHPFDQFHU
  20. Laurent S, Bruno RM. Gut micro-biome composition, a third player LQ WKH LQʗDPPDWLRQDUWHULDO VWLII-ness relationship. Eur Heart J. Jul 1 GRL HXUKHDUWMHK
  21. Chan YK, Brar MS, Kirjavainen PV, et al. High fat diet induced atheroscle-rosis is accompanied with low colonic bacterial diversity and altered abun-dances that correlates with plaque size, plasma A-FABP and cholester-RODSLORWVWXGRIKLJKIDWGLHWDQG its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan LQ $SR( PLFH %0& 0LFURELRO 1RY GRL s12866-016-0883-4
  22. Zdimal AM, Davies DG. Laboratory *URZQ%LRʖOPVRI%DFWHULD$VVRFLDW-ed with Human Atherosclerotic Ca-rotid Arteries Release Collagenases and Gelatinases during Iron-Induced Dispersion. Microbiol Spectr. Jun 29 H GRL spectrum.01001-21
  23. Ciccone MM, Lepera ME, Guaricci AI, et al. Might Gut Microbiota Be a Target for a Personalized Therapeu-tic Approach in Patients Affected by Atherosclerosis Disease? J Pers 0HG 6HS GRL jpm13091360 24. van den Munckhof ICL, Kurilshikov A, Ter Horst R, et al. Role of gut micro-ELRWD LQ FKURQLF ORZJUDGH LQʗDP-mation as potential driver for ath-HURVFOHURWLFFDUGLRYDVFXODUGLVHDVH a systematic review of human stud-LHV2EHV5HY'HF GRLREU
  24. Kasselman LJ, Vernice NA, DeLeon J, Reiss AB. The gut microbiome and el-evated cardiovascular risk in obesity and autoimmunity. Atherosclerosis. $SUGRLM atherosclerosis.2018.02.036
  25. Szabo H, Hernyes A, Piroska M, et al. Association between Gut Microbial Diversity and Carotid Intima-Media Thickness. Medicina (Kaunas). Feb GRLPHGLFL-na57030195
  26. Emoto T, Yamashita T, Kobayashi T, et al. Characterization of gut microbio-WDSURʖOHVLQFRURQDUDUWHUGLVHDVH patients using data mining analy-sis of terminal restriction fragment OHQJWKSROPRUSKLVPJXWPLFURELRWD could be a diagnostic marker of cor-onary artery disease. Heart Vessels. -DQ GRL s00380-016-0841-y
  27. Guevara-Cruz M, Flores-Lopez AG, Aguilar-Lopez M, et al. Improvement RI/LSRSURWHLQ3URʖOHDQG0HWDEROLF Endotoxemia by a Lifestyle Inter-YHQWLRQ 7KDW 0RGLʖHV WKH *XW 0L-crobiota in Subjects With Metabolic Syndrome. J Am Heart Assoc. Sep H GRL JAHA.119.012401
  28. Liu H, Chen X, Hu X, et al. Alter-ations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. Apr GRLV 019-0683-9
  29. Jie Z, Xia H, Zhong SL, et al. The gut microbiome in atherosclerotic car-diovascular disease. Nat Commun. 2FW GRL s41467-017-00900-1
  30. Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia Muciniphila Protects Against Atherosclerosis by Prevent-ing Metabolic Endotoxemia-Induced ,QʗDPPDWLRQ LQ $SRH 0LFH &LU-FXODWLRQ -XQ GRL&,5&8/$7,21$-HA.115.019645
  31. Hasani A, Ebrahimzadeh S, Hemmati DŽLJǓǔǏNJnjǗNJǒǕǒDžNJNJnjǂljǂǗǓǔǂǏǂɫ 12 FROM GUT TO PLAQUE: GUT MICROBIOME'S IMPACT ON ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSION. LITERATURE REVIEW F, Khabbaz A, Hasani A, Gholizadeh P. The role of Akkermansia muciniphila in obesity, diabetes and atherosclero-VLV-0HG0LFURELRO2FW GRL MPP
  32. Chen L, Ishigami T, Doi H, Arakawa K, Tamura K. The Types and Pro-portions of Commensal Microbiota Have a Predictive Value in Coronary Heart Disease. J Clin Med. Jul 15 GRLMFP
  33. Li C, Strazar M, Mohamed AMT, et al. Gut microbiome and me-WDERORPH SURʖOLQJ LQ )UDPLQJ-ham heart study reveals choles-terol-metabolizing bacteria. Cell. $SU H GRLMFHOO
  34. Nesci A, Carnuccio C, Ruggieri V, et al. Gut Microbiota and Cardiovascu-ODU 'LVHDVH (YLGHQFH RQ WKH 0HWD-EROLFDQG,QʗDPPDWRU%DFNJURXQG of a Complex Relationship. Int J Mol 6FL 0D GRL ijms24109087
  35. Oliphant K, Allen-Vercoe E. Macro-nutrient metabolism by the human JXW PLFURELRPH PDMRU IHUPHQWD-tion by-products and their impact on host health. Microbiome. Jun 13 GRLV 019-0704-8
  36. Valdes AM, Walter J, Segal E, Spec-tor TD. Role of the gut microbiota in nutrition and health. BMJ. Jun 13 N GRLEPM k2179
  37. Li B, Xia Y, Hu B. Infection and DWKHURVFOHURVLV 7/5GHSHQGHQW pathways. Cell Mol Life Sci. Jul GRL s00018-020-03453-7
  38. Jing J, Guo J, Dai R, Zhu C, Zhang Z. Targeting gut microbiota and immune FURVVWDON SRWHQWLDO PHFKDQLVPV RI natural products in the treatment of atherosclerosis. Front Pharma-FRO GRL fphar.2023.1252907
  39. Du Y, He C, An Y, et al. The Role of 6KRUW &KDLQ )DWW $FLGV LQ ,QʗDP-mation and Body Health. Int J Mol 6FL -XO GRL ijms25137379
  40. Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intesti-nal barrier dysfunction and risk for enteric infection. Science. Mar GRLVFLHQFHDDU
  41. Chen W, Zhang S, Wu J, et al. Butyr-ate-producing bacteria and the gut-heart axis in atherosclerosis. Clin &KLP $FWD $XJ GRLMFFD
  42. He J, Zhang P, Shen L, et al. Short-Chain Fatty Acids and Their As-sociation with Signalling Path-ZDV LQ ,QʗDPPDWLRQ *OXFRVH and Lipid Metabolism. Int J Mol 6FL 6HS GRL ijms21176356
  43. Hosseinkhani F, Heinken A, Thiele I, Lindenburg PW, Harms AC, Hanke-meier T. The contribution of gut bacterial metabolites in the hu-man immune signaling pathway of non-communicable diseases. Gut 0LFUREHV -DQ'HF GRL
  44. Zhang D, Jian YP, Zhang YN, et al. Short-chain fatty acids in diseas-es. Cell Commun Signal. Aug 18 GRLV 023-01219-9
  45. Martin-Gallausiaux C, Marinelli L, %ORWWLHUH +0 /DUUDXʖH 3 /DSDTXH 16&)$PHFKDQLVPVDQGIXQFWLRQDO importance in the gut. Proc Nutr Soc. )HE GRL S0029665120006916
  46. Li M, van Esch B, Henricks PAJ, Folk-HUWV**DUVVHQ-7KH$QWLLQʗDP-matory Effects of Short Chain Fatty Acids on Lipopolysaccharide- or Tu-mor Necrosis Factor alpha-Stimu-lated Endothelial Cells via Activation RI*35DQG,QKLELWLRQRI+'$&V )URQW 3KDUPDFRO GRLISKDU
  47. Yoo JY, Sniffen S, McGill Percy KC, Pallaval VB, Chidipi B. Gut Dysbio-sis and Immune System in Athero-sclerotic Cardiovascular Disease (ACVD). Microorganisms. Jan 5 GRLPLFURRUJDQ-isms10010108
  48. Tian Q, Leung FP, Chen FM, et al. Butyrate protects endothelial func-WLRQ WKURXJK 33$5GHOWDPL5E signaling. Pharmacol Res. Jul GRLM phrs.2021.105681
  49. Pagonas N, Seibert FS, Liebisch G, %8//(7,12)685*(5<,1.$=$.+67$1ɫ 13 FROM GUT TO PLAQUE: GUT MICROBIOME'S IMPACT ON ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSION. LITERATURE REVIEW et al. Association of plasma propi-onate concentration with coronary artery disease in a large cross-sec-tional study. Front Cardiovasc Med. GRL fcvm.2023.1063296
  50. Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in KXPDQKHDOWK(;&/,- GRLH[FOL
  51. Velasquez MT, Ramezani A, Manal $5DM'67ULPHWKODPLQH12[LGH The Good, the Bad and the Unknown. 7R[LQV %DVHO 1RY GRLWR[LQV
  52. Yang S, Li X, Yang F, et al. Gut Mi-crobiota-Dependent Marker TMAO in Promoting Cardiovascular Dis-HDVH ,QʗDPPDWLRQ 0HFKDQLVP Clinical Prognostic, and Potential as a Therapeutic Target. Front Phar-PDFRO GRL fphar.2019.01360
  53. Guasch-Ferre M, Hu FB, Ruiz-Cane-la M, et al. Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Med-iterranean Diet) Study. J Am Heart $VVRF2FWGRL JAHA.117.006524
  54. Hoseini-Tavassol Z, Hasani-Ranjbar S. Targeting TMAO and its metabol-ic pathway for cardiovascular dis-eases treatment. J Diabetes Metab 'LVRUG -XQ GRLV[
  55. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Micro-bial Trimethylamine Production for the Treatment of Atherosclerosis. &HOO 'HF GRLMFHOO
  56. Janeiro MH, Ramirez MJ, Milagro FI, Martinez JA, Solas M. Implication of Trimethylamine N-Oxide (TMAO) in 'LVHDVH3RWHQWLDO%LRPDUNHURU1HZ Therapeutic Target. Nutrients. Oct 1 GRLQX
  57. Jin Q, Zhang C, Chen R, et al. Quin-LFDFLGUHJXODWHG70$70$2UHODWHG lipid metabolism and vascular en-dothelial function through gut mi-crobiota to inhibit atherosclerotic. J 7UDQVO 0HG $SU GRLV
  58. Liu Y, Dai M. Trimethylamine N-Ox-ide Generated by the Gut Micro-biota Is Associated with Vascu-ODU ,QʗDPPDWLRQ 1HZ ,QVLJKWV into Atherosclerosis. Mediators ,QʗDPP GRL
  59. Guo D, Shen Y, Li W, Li Q, Miao Y, =KRQJ<8SUHJXODWLRQRIʗDYLQFRQ-taining monooxygenase 3 mimics calorie restriction to retard liver ag-ing by inducing autophagy. Aging (Al-EDQ1<-DQ GRLDJLQJ
  60. Zhu W, Buffa JA, Wang Z, et al. Flavin monooxygenase 3, the host hepatic enzyme in the metaor-ganismal trimethylamine N-ox-ide-generating pathway, modulates platelet responsiveness and throm-bosis risk. J Thromb Haemost. Sep GRL jth.14234
  61. Tremaroli V, Backhed F. Function-al interactions between the gut mi-crobiota and host metabolism. Na-WXUH 6HS GRLQDWXUH
  62. Qi S, Luo X, Liu S, Ling B, Jin H. The Critical Effect of Bile Acids in Ath-erosclerosis. J Cardiovasc Phar-PDFRO 2FW GRL)-&
  63. Chiang JYL, Ferrell JM. Bile acid re-ceptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physi-RO 0DU ** GRLDMSJL
  64. Gorabi AM, Kiaie N, Khosrojerdi A, et al. Implications for the role of lipo-polysaccharide in the development of atherosclerosis. Trends Cardio-YDVF 0HG 1RY GRLMWFP
  65. Molteni M, Gemma S, Rosset-ti C. The Role of Toll-Like Re-ceptor 4 in Infectious and 1RQLQIHFWLRXV ,QʗDPPDWLRQ 0HGL-DWRUV ,QʗDPP GRL
  66. Suzuki K, Susaki EA, Nagaoka I. Lipo-polysaccharides and Cellular Senes-FHQFH,QYROYHPHQWLQ$WKHURVFOHUR-VLV,QW-0RO6FL6HS GRLLMPV
  67. Wang H, Fu H, Zhu R, et al. BRD4 contributes to LPS-induced mac-DŽLJǓǔǏNJnjǗNJǒǕǒDžNJNJnjǂljǂǗǓǔǂǏǂɫ 14 FROM GUT TO PLAQUE: GUT MICROBIOME'S IMPACT ON ATHEROSCLEROSIS DEVELOPMENT AND PROGRESSION. LITERATURE REVIEW rophage senescence and promotes progression of atherosclerosis-as-sociated lipid uptake. Aging (Albany 1< 0D GRLDJLQJ
  68. Ziolkiewicz A, Kasprzak-Drozd K, Rusinek R, Markut-Miotla E, 2QLV]F]XN$7KH,QʗXHQFHRI3RO-phenols on Atherosclerosis Develop-PHQW,QW-0RO6FL$SU GRLLMPV
  69. Sorrenti V, Ali S, Mancin L, Davinelli S, Paoli A, Scapagnini G. Cocoa Poly-phenols and Gut Microbiota Inter-SOD%LRDYDLODELOLW3UHELRWLF(IIHFW and Impact on Human Health. Nutri-HQWV -XQ GRL nu12071908 7KHRʖOLV32LNRQRPRX(&KDVLNLGLV & 7VLRXʖV . 7RXVRXOLV ' ,QʗDP-masomes in Atherosclerosis-From Pathophysiology to Treatment. Pharmaceuticals (Basel). Aug 28 GRLSK
  70. Al-Hawary SIS, Jasim SA, Rome-UR3DUUD 50 HW DO 1/53 LQʗDP-PDVRPHSDWKZDLQDWKHURVFOHURVLV Focusing on the therapeutic po-tential of non-coding RNAs. Pathol 5HV 3UDFW -XQ GRLMSUS
  71. Zhai T, Wang P, Hu X, Zheng L. Probi-otics Bring New Hope for Atheroscle-rosis Prevention and Treatment. Oxid 0HG&HOO/RQJHY GRL :X+&KLRX-3RWHQWLDO%HQHʖWVRI Probiotics and Prebiotics for Coro-nary Heart Disease and Stroke. Nutri-HQWV $XJ GRL nu13082878
  72. Kim ES, Yoon BH, Lee SM, et al. Fe-cal microbiota transplantation ame-liorates atherosclerosis in mice ZLWK &T71)UHODWHG SURWHLQ JH-QHWLF GHʖFLHQF ([S 0RO 0HG )HE GRL s12276-022-00728-w

Жарияланды

2025-06-30

Журналдың саны

№ 2 (2025)

Бөлім

Статьи